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In the central nervous system, the inhibitory GABAB receptor is the archetype
of heterodimeric G protein-coupled receptors (GPCRs). Receptor interaction with
partner proteins has emerged as a novel mechanism to alter GPCR signaling in
pathophysiological conditions. We propose here that GABAB activity is inhibited through
the specific binding of fibulin-2, an extracellular matrix protein, to the B1a subunit
in a rat model of neuropathic pain. We demonstrate that fibulin-2 hampers GABAB
activation, presumably through decreasing agonist-induced conformational changes.
Fibulin-2 regulates the GABAB-mediated presynaptic inhibition of neurotransmitter
release and weakens the GABAB-mediated inhibitory effect in neuronal cell culture. In
the dorsal spinal cord of neuropathic rats, fibulin-2 is overexpressed and colocalized
with B1a. Fibulin-2 may thus interact with presynaptic GABAB receptors, including
those on nociceptive afferents. By applying anti-fibulin-2 siRNA in vivo, we enhanced
the antinociceptive effect of intrathecal baclofen in neuropathic rats, thus demonstrating
that fibulin-2 limits the action of GABAB agonists in vivo. Taken together, our data
provide an example of an endogenous regulation of GABAB receptor by extracellular
matrix proteins and demonstrate its functional impact on pathophysiological processes
of pain sensitization.
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INTRODUCTION
G protein-coupled receptors (GPCRs) modulate a wide range of physiological processes and
new drug candidates are continually being developed for selective GPCRs (Lagerstrom and
Schioth, 2008; Hauser et al., 2017; Topiol, 2018). Functional GABAB receptors are expressed as
obligate heterodimers of the two subunits GABAB1 (B1) and GABAB2 (B2) (Jones et al., 1998;
Kaupmann et al., 1998), and GABAB-mediated inhibition is an essential control of neuronal
activity throughout the central nervous system. GABAB receptor subunits bind several partner
proteins (Bettler et al., 2004; Pin and Bettler, 2016; Fritzius et al., 2017) that regulate the receptor
activation in pathophysiological conditions such as chronic pain (Laffray et al., 2007; Laffray
et al., 2012; Zemoura et al., 2016; Malcangio, 2018). Among these binding partners, extracellular
matrix (ECM) proteins have been shown to regulate postsynaptic GABAB-mediated inhibition
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(Saghatelyan et al., 2003). However, the importance of such
interaction in a pathophysiological context has not been
established yet.
In the central nervous system, aggregates of ECM molecules
appear as so-called perineuronal nets that surround soma and
dendrites (Fawcett et al., 2019). These nets are heterogeneous
in structure and composition, incorporating proteins derived
from both neuronal and glial cells. The expression of ECM
proteins is developmentally and spatially regulated in the central
nervous system. Some of these molecules are up-regulated
following adult nerve injury (Quraishe et al., 2018; Roumazeilles
et al., 2018) and ECM proteins have been implicated in
synaptic differentiation and plasticity (Rowlands et al., 2018).
The emerging mechanisms comprise clustering of receptors
and changes in their composition and function (Dityatev and
Schachner, 2006; Ferrer-Ferrer and Dityatev, 2018). To date,
beside the specific class of adhesion GPCR (Langenhan et al.,
2016) only very rare studies have considered interactions between
ECM proteins and GPCRs (Saghatelyan et al., 2003; Yeh et al.,
2008) and the mechanisms by which ECM proteins regulate
GPCR activation in neurons remains largely unknown.
In this context, the present study focuses on the role of fibulin-
2, an extracellular binding partner of the B1a variant of GABAB1
subunit (Blein et al., 2004) that is mainly found in presynaptic
compartments (Vigot et al., 2006). We demonstrate that fibulin-
2 up-regulation hampers GABAB activation and signaling by
agonists. In contrast, we show that the loss of fibulin-2 facilitates
agonist-induced activation of the GABAB receptor and decreases
the efficiency of antagonists. Therefore, we suggest that fibulin-
2 may limit conformational changes that are necessary for
the receptor activation, and facilitate an inactive conformation
of the receptor.
As a functional consequence of this mechanism, we
demonstrate in a primary cell culture model that fibulin-2
regulates the GABAB-mediated presynaptic inhibition of
neurotransmitter release. We further show the physiological
impact of this mechanism on neuropathic pain sensitization
in the dorsal horn of the rat spinal cord. Our data indicated
fibulin-2 up-regulation in the dorsal spinal cord of neuropathic
rats. In such chronic pain conditions, the efficiency of GABAB-
mediated inhibition was improved by knocking-down the
protein expression with in vivo application of anti-fibulin-2 small
interference (si) RNA.
Finally, our demonstration that the fibulin-2 endogenous
extracellular matrix protein inhibits GPCR activity in a
pain context highlights a novel mechanism of disinhibition,




Neuronal cells were obtained from rats (Sprague Dawley) at
18 days of embryonic development. The embryos were delivered
by cesarean section from deeply anesthetized rats and killed by
decapitation. Pieces of lumbar region of the spinal cord or cortex
were exposed to a 1X trypsin solution (Gibco) for 25 min at
37◦C. These pieces were then mechanically dissociated by forcing
them through fine-tipped pipettes several times. Cells were plated
on glass coverslips at a density of 150,000/100 µL. The glass
coverslips were previously coated overnight at 37◦C with a
0.1 mg/mL polylysine solution for cortex and 1 mg/mL for spinal
cord (Sigma, Saint Louis, MO, United States) and for 2 h with a
0.05 mg/mL laminine solution (Sigma). The cultures were kept
in Serum-free Neurobasal TM medium (Gibco), supplemented
with B27 (Gibco) and Glutamax (Gibco). Half of the medium was
changed twice a week.
Dissociated rat spinal neurons, cultured in Serum-free
Neurobasal TM medium (Gibco, ThermoFisher, Waltham,
MA, United States), were transfected with 400 ng plasmid
DNA/2 µL Lipofectamine 2000 (Invitrogen, Cergy Pontoise,
France). In most cases, transfected cells incorporated all cDNAs
together. siRNA was added 24 h after transfection with cDNAs
(500 ng siRNA/3µL of Lipofectamine 2000). Growth medium
was replaced after 6 h and cells were harvested 36 h after
siRNA transfection.
Plasmids and siRNAs
For Fluorescence (or Förster) Resonance Energy Transfer (FRET)
experiments, B1a/B1b, and B2 cDNA were modified at their
N-terminus by the addition of Green Fluorescent Protein (GFP),
or tandem-dimer discosoma red fluorescent protein (t-dimer
DsRed), respectively (Laffray et al., 2007, 2012). DsRed-GABAB2
was subcloned in the pcDNA3.1 mammalian expression vector.
GABAB1a/b were subcloned in the pEGFP-C3 to express GFP
at the N-terminus. For co-immunoprecipitation experiments,
myc-GABAB1a/b and HA-GABAB2 expressing plasmids were
transfected with Lipofectamine 2000 (Invitrogen) in COS-7 cells
as described previously (Laffray et al., 2012). The Rc/CMV vector
containing the full-length fibulin-2 construct was obtained from
Dr. Takako Sasaki (Max-Planck-Institut, Martinsried, Germany)
and was prepared as described (Pan et al., 1993; Sasaki et al.,
1995, 1996). Fibulin-2-Flag was co-expressed in COS-7 cells
with hemagglutinin (HA)-GABAB2 and myc-GABAB1a/b. Anti-
fibulin-2 siRNA was a pool of 3 target-specific 20-25 nucleotides
siRNAs (sc-43120, Santa Cruz Biotechnology, Santa Cruz, CA,
United States). Mismatch siRNA was a non-targeting 20–25
nucleotides designed as a negative control (sc-37007, Santa
Cruz Biotechnology).
The efficacy of siRNA to downregulate the expression of
fibulin-2 mRNA was assessed by SYBRGreen-based quantitative
reverse transcription – polymerase chain reaction (qRT-PCR)
both on cell cultures (data not shown) and after intrathecal
injections in-vivo (see Results section, Expression of Fibulin-2 in
vivo).
qRT-PCR
Expression analysis of fibulin-1 and fibulin-2 mRNA was
performed with the DyNAmoTM SYBR Green qPCR kit
(Finnzymes, Espoo, Finland). Triplicate runs were performed
and Succinate dehydrogenase Complex, Subunit A (SDHA)
was used as a normalizer. The relative level of expression
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was calculated using the comparative (211CT) method
(Livak and Schmittgen, 2001).
Spectral and Lifetime Correlated
Acquisitions
Spinal cultures were treated for 1 h or 15 min at 37◦C with fibulin-
2 protein at 25 or 50 nM. Then, cultures were treated for 30 min
at 37◦C with baclofen (10−3 M to 10−9 M, Sigma B5399), or with
GABA (10−4 M, Sigma A5835); or with competitive antagonists
CGP55485 (0.5 or 50 µM, Tocris 55845) or saclofen (100 µM
or 1 mM, Sigma S166) co-applied with baclofen. Next, cells
were fixed 20 min at 37◦C [4% paraformaldehyde, 4% sacharose
in phosphate buffer (PB) 0.1M, pH 7.4], washed [0.1M PB
saline (PBS), 10 min at RT] and mounted on slides (Fluorescent




The interaction between GFP-tagged proteins and t-dimer
DsRed-tagged proteins was studied as described previously
(Laffray et al., 2007, 2012) using quantitative FRET (Fluorescence
or Förster Resonance Energy Transfer) determination with FLIM
(Fluorescence Lifetime Imaging Measurements) using Time
Correlated-Single Photon Counting (Becker and Hickl, Berlin,
Germany). To assess protein interactions, we calculated a relative
FRET efficiency for each acquisition as follow: FRET Efficiency
(%) = (τDmean-τDA)/τDmean × 100 where τ is the time constant
of the exponential fit with τDmean being the mean lifetime of
the donor fluorophore (GFP) when expressed alone and τDA
being the lifetime of the donor fluorophore in the presence of
the acceptor (t-dimer DsRed). Results were expressed as a mean
FRET efficiency (n = 21 cells or more in each condition) ± SEM.
Due to the mono-exponential decay of GFP and their
spectra compatibility, the GFP-DsRed couple is very well suited
for quantitative FRET determination with FLIM (Fluorescence
Lifetime Imaging Measurements) (Tramier et al., 2002; Stubbs
et al., 2005). Moreover, the t-dimer DsRed is a tandem of
monomeric red fluorescent protein that matures rapidly, does
not form aggregates, and has minimal emission when excited
at 900 nm, a wavelength optimal for GFP and minimizing the
excitation of t-dimer DsRed (Campbell et al., 2002).
The interaction between GFP-tagged protein and t-dimer
DsRed-tagged protein was studied using two-photon-
Fluorescence Lifetime Imaging Measurement (2P-FLIM)
with the SPCM and SPC Image software (Becker & Hickl).
For GFP excitation, we used a two-photon pulsed excitation
(890 nm), given by the Coherent Mira 900-F laser 5W (Coherent
inc. Laser Group, Santa Clara, CA, United States). All acquisitions
were undertaken with a 100x, 1.4NA, Leica oil objective lens on a
Leica TCS SP2 inverted confocal microscope. The laser repetition
frequency was 76 MHz which gave a 12 ns temporal window for
lifetime measurements. Photon detection was performed in cells
using the SPRC160, a homemade system based on a 16 channel
multi-anode photomultiplier head (PML16, Becker&Hickl) and a
concave holographic grating allowing spectral dispersion on the
detector. The Becker & Hickl TCSPC 730 card (Becker & Hickl,
Berlin, Germany) determined the time between fluorophore
excitation and photon emission, as well as routing information
associated to spectral range. This card was driven by the SPCM
software which allowed fluorescence decay curve measurements
using a single-spot mode; and fluorescence decay curve fits,
allowing lifetime determination were obtained using the SPC
Image software (both software from Becker & Hickl). The
choice between mono-exponential decay and bi-exponential
decay fitting was done using the reduced χ2 parameter. Lifetime
values were extracted from three spectral channels, from 494 to
542 nm, and averaged. To ensure reliability of our measurements,
we checked the lifetime stability upon this spectral range. As
a second control, the first channels were used to ensure no
autofluorescence in measured cells, which otherwise could result
in artefactual FRET positive response.
Co-immunoprecipitation
The co-immunoprecipitation experiments were performed in
COS-7 cells after transfection, according to the previously
described procedure (Laffray et al., 2012). Briefly, total protein
extract was homogenized in ice-cold PBS containing 1% CHAPS,
25 mM Hepes and 150 mM NaCl, and protease inhibitors,
pH 7.4. Homogenates were incubated overnight with 50 µl
of magnetic beads (protein-A sepharose, Sigma) at 4◦C. After
centrifugation, the supernatants were transferred to the tube
containing 5 µg of specific anti-myc (Roche) or anti-flag
(Sigma) antibodies. Then, samples were washed twice, incubated
in Laemmli buffer (Sigma) and subjected to Western blot
detection. After electrophoresis using sodium dodecyl sulfate –
polyacrylamide gel electrophoresis (SDS–PAGE), samples were
transferred to polyvinylidene difluoride (PVDF) membranes.
Blots were blocked in 5% skimmed milk for 30 min and then
incubated with antibodies (mouse anti-myc, 1/1000, Roche;
guinea pig anti-flag, Sigma; mouse anti-GABAB2, 1/1000,
Eurobio, Les Ulis, France) at 4◦C overnight. Then detection
was performed with the appropriate HRP-conjugated secondary
antibodies at 1/1000 for 1 h30 (anti-mouse or anti-guinea-
pig, Dako products, Agilent). Immunoreactivity was developed
using the enhanced chemiluminescent method and visualized




Rats were perfused with 4% paraformaldehyde. For electron
microscopy, glutaraldehyde (0.2%) was added to the fixative
solution. The lumbar spinal cord was rapidly dissected out, and
post-fixed for 2 h in 4% paraformaldehyde. Tissue samples were
then processed for light or electron microscopy.
For light microscopy, transverse spinal cord sections were
cut at 30 µm thickness on a cryostat (Microm) and processed
for double-fluorescent labeling experiments. Sections were
incubated overnight at 4◦C with a goat anti-fibulin-2 (1/400,
Santa Cruz) and a sheep anti-GABAB1a (1/20,000; gift from Dr.
Andrew Calver, GlaxoSmith Kline, Harlow, United Kingdom).
Subsequently, GABAB1a was visualized with a biotinylated
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secondary antibody and a tyramide-based method (Landry
et al., 2004) using FITC-conjugated tyramide (PerkinElmer
Life Sciences, Boston, MA, United States). Fibulin-2 was
detected with a biotinylated secondary antibody and Alexa568-
conjugated streptavidin (Molecular Probes Inc., Eugene,
OR, United States).
For co-detection of fibulin-2 and calcitonin gene-related
peptide (CGRP), sections were incubated overnight at 4◦C
with goat anti-fibulin-2 (1/400, Santa Cruz) and rabbit anti-
CGRP (1/1000, Peninsula). Subsequently, fibulin-2 was detected
with biotinylated secondary antibody and Alexa568-conjugated
streptavidin (Molecular Probes Inc., Eugene, OR, United States).
CGRP was visualized with Alexa 488-conjugated anti-rabbit
(Molecular Probes Inc., Eugene, OR, United States). Sections
were viewed with a confocal microscope (Leica DMR TCS SP2
AOBS, Mannheim, Germany).
For electron microscopy, Vibratome R© sections were cut
at 200 µm thickness and samples of superficial spinal cord
laminae (I-II) were embedded in Lowicryl R© HM20 resin (EMS,
Hatfield, PA, United States) with the progressive lowering of
temperature method, using the Reichert AFS system (Leica,
Wien, Austria) according to the instruction manual. Ultrathin
sections (70 nm) from Lowicryl blocks were collected on
butvar-coated single-slotted nickel grids (EMS) and submitted
to postembedding immunogold multiple labeling. GABAB
receptor subunits and fibulin-2 protein were detected with:
anti-GABAB1a (1/100, sheep, Glaxo), and anti-fibulin-2 (1/500,
goat, Santa Cruz) primary antibodies and visualized with the
appropriate colloidal gold-conjugated detection systems (BBI,
Cardiff, United Kingdom; EMS) (GABAB1a = 15 nm, fibulin-
2 = 5 nm). Grids were rapidly fixed for 1 min in 1%
glutaraldehyde diluted in water. After rinsing, grids were finally
stained with 2% uranyl acetate in water for 12 min and examined
with a Hitachi H7650 electron microscope (Elexxience, Verrières-
le-buisson, France) equipped with an Orius SC1000 camera
(GATAN, Evry, France).
CGRP and fibulin-2 protein were detected with anti-
CGRP (1/500, rabbit, Peninsula), and anti-fibulin-2 (1/500,
goat, Santa Cruz) primary antibodies and visualized with the
appropriate colloidal gold-conjugated detection systems (BBI,
Cardiff, United Kingdom; EMS) (CGRP = 5 nm and fibulin-
2 = 15 nm).
Immunostaining of the spinal cord was visualized under
a SPE confocal microscope (Leica Microsystems). Images
to be compared were collected during the same session
using identical scanning settings. They were then imported
into “ImageJ” free software (version 1.42q) (NIH, Bethesda,
MA, United States) for quantitative analysis. Background was
subtracted by thresholding. For fibulin-2 and GABAB1a intensity
assessment, the mean gray level corresponding to fluorescence
intensity was measured (Zaky et al., 2018). Results were expressed
as a percentage of the intensity in sham animals. Counting was
performed on 5 sections per rat, 8 (fibulin-2) or 4 (GABAB1a)
rats per condition (sham or SNL). The extent of colocalization
between fibulin-2 and GABAB1a was quantitatively assessed
using a semi-automatized procedure with the Image J software
(Landry et al., 2004; Zaky et al., 2018). After thresholding,
colocalization area was assessed in the entire fields acquired in
the dorsal horn of the spinal cord (4 sections per rat, 8 rats per
condition). Results were expressed as a percentage of GABAB1a
total labeling that is seen in the area.
Patch Clamp
For voltage-clamp recordings, 8–10 days-aged cultured spinal
neurons on their coverslip were submerged in normal Krebs
solution containing 130.5 mM NaCl, 2.4 mM KCl, 2.4 mM
CaCl2, 19.5 mM NaHCO3, 1.3 mM MgSO4, 1.2 mM KH2PO4,
1.25 mM HEPES, 10.0 mM glucose, pH 7.4, equilibrated with
95% O2 and 5% CO2, at room temperature (20–23◦C). The
coverslip was placed in a chamber and visualized by means of
infrared DIC video-microscopy using an upright microscope
BX51WI (Olympus France, Rungis, France) equipped with a
40x water immersion lens (LUMPlanFI/IR), and a CCD camera
C2400-03 (Hamamatsu, Hamamatsu City, Japan). The culture
was continuously superfused with Kreb solution at 1.6 mL.mn−1.
Patch pipettes (6–8 M ) were filled with 120 mM potassium
gluconate, 20 mM KCl, 0.1 mM CaCl2, 1.3 mM MgCl2, 1 mM
EGTA, 10 mM HEPES, 0.1 mM GTP, 0.2 mM cAMP, 0.1 mM
leupeptin, 3 mM Na2-ATP and 77 mM D-mannitol, pH 7.3. Series
resistance was negligible.
Miniature EPSCs were recorded in voltage clamp mode
(holding potential −60 mV) in the presence of 10−6 M
Tetrodotoxin (TTX). In such experimental conditions, no action
potential could be evoked following injection of positive current
into the recorded neuron, demonstrating a complete blockade
of action potential propagation. Signals were amplified using an
Axoclamp 2B amplifier and digitized at 10 kHz. Individual events
were extracted from raw data using mini-analysis software1
over a duration of 2 min and visually filtered according to
their general shape.
GTPγS Binding and Competition Binding
Assay
Membrane Preparation
Primary cell cultures of rat cortex (8 million of cells/mL) were
homogenized using a Teflon glass grinder (10 up-and-down
strokes at 1500 rpm) in 5 ml of homogenization buffer (1 mM
EGTA, 3 mM MgCl2 and 50 mM Tris-HCl, pH 7.4) supplemented
with 0.25 mM sucrose. The crude homogenate was centrifuged
for 5 min at 500 rpm (4◦C) and the supernatant was recentrifuged
for 10 min at 18000 rpm (4◦C). The resultant pellet was washed
in 4 ml of homogenization buffer and recentrifuged in similar
conditions. Aliquots of protein were stored at –80◦C until assay.
Protein content was measured according to the method of
Bowery (2006) using bovine serum albumin (BSA) as standard.
[35S]GTPγS Binding Assays
Membrane aliquots were thawed and resuspended in a buffer
containing 1mM EGTA, 3 mM MgCl2, 100 mM NaCl, 3 mU/ml
adenosine deaminase and 50 mM Tris-HCl, at pH 7.4. The
incubation was started by addition of the membrane suspension
(400 microliters of membranes in each tube at a protein
1http://www.synaptosoft.com/
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concentration of 0.1 mg/ml) to the previous mixture of 0.5 nM
[35S]GTPγS, 50 µM GDP and appropriate concentrations
of drugs and was performed at 30◦C for 120 min with
shaking. Incubations were terminated by adding 3 ml of ice-
cold resuspension buffer followed by rapid filtration through
Whatman GF/C filters presoaked in the same buffer. The
filters were rinsed twice with ice-cold resuspension buffer,
transferred to vials containing 5 ml of OptiPhase HiSafe
II cocktail and the radioactivity trapped was determined by
liquid scintillation spectrometry (Packard 2200CA). Non-specific
binding was defined as the remaining [35S]GTPγS binding in
the presence of 10 µM unlabelled GTPγS. Non-specific binding
was subtracted from total bound radioactivity to determine
[35S]GTPγS specific binding.
Competition Binding Assay
The mixture for the binding assay contained Hanks’ Balanced
Salt Solution (HBSS) (NaCl, 8 g/l; CaCl2, 0.14 g/l; KCl, 0.40 g/l;
NaHCO3, 0.35 g/l; glucose, 1 g/l; MgCl2 6H2O, 0.10 g/l; KH2PO4,
0.06 g/l; MgSO4 7H2O, 0.10 g/l and Na2HPO4, 0.05 g/l, pH 7.4),
the membrane suspension (2.07 µg of membrane proteins) and
2 nM [3H]-CGP54626 with or without different concentrations
of baclofen in a final volume of 0.5 ml. The mixture was incubated
at 5◦C for 20 min, and then the reaction was terminated by
adding ice-cold wash buffer followed by rapid filtration through
Whatman GF/C filters (presoaked with 0.33% polyethyleneimine
with 50 mM Tris-Cl, pH 7.4, for 30 min). The filters were rinsed
twice with ice-cold wash buffer, transferred to vials containing
5 ml of OptiPhase HiSafe II cocktail and the radioactivity
trapped was determined by liquid scintillation spectrometry
(Packard 2200CA).
Animal Models and Behavioral Tests
Adult male Wistar rats (250–300 g; Charles River France, St
Aubin les Elbeuf, France) were used. The experiments followed
the ethical guidelines of the International Association for the
Study of Pain and were approved by the local ethics committee
in Bordeaux (AP 1/04/2005). Persistent neuropathic pain in rats
was evoked by ligation of the right L5-L6 spinal nerve (Spinal
Nerve Ligation, SNL) (Decosterd and Woolf, 2000). Mechanical
response thresholds were monitored in SNL, and sham-operated
(sciatic nerve was exposed but the L5 and L6 sciatic nerves were
not ligated) animals at 1 day before surgery (reference value
for each animal), and at day 12 (before and after intrathecal
injections of baclofen) and at day 15 (24 h after the last siRNA
injection). Rats were placed in the testing cage 1 h before the
test for habituation. The withdrawal threshold of the leg on the
operated side was determined in response to mechanical stimuli
applied to the plantar surface of the foot. The limb withdrawal
threshold was measured by an electronic device (Bioseb, France)
that was derived from Von Frey filaments (Kalmar et al., 2003;
Lever et al., 2003). Sham-operated rats were used as controls.
In vivo Intrathecal Injections and
Mechanical Allodynia
For intrathecal injections of baclofen or RNAs (anti-fibulin-2
siRNA or mismatch RNA), sham and SNL rats were implanted
with a catheter (PE-10; Phymep, France) inserted into the
subarachnoid space (Fossat et al., 2007). The threshold to
mechanical stimulation was monitored before and after surgery,
and after the various injections. Results were expressed as
percentages of changes in the threshold of neuropathic rats.







day -1 day 12 day 13 day 14 day 15day 0
von Frey Test
- von Frey test
- baclofen injecon
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- RNA injecon
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- von Frey test aer 1hr
Rats were tested for mechanical allodynia before surgery (day-
1, reference value set to 100%). The threshold to mechanical
stimulation was monitored again in sham-operated and SNL
animals 12 days after surgery (day 12), after baclofen injection
(1 µg in 10 µL; Sigma B5399) on the same day (day 12, baclofen),
on day 15 after injection of anti-fibulin-2 siRNA or mismatch
RNA (day 15, RNA), and finally after baclofen injection on
the same day (day 15, RNA + baclofen). Anti-fibulin-2 siRNA
(siRNA) and mismatch RNA (mmRNA) were injected daily
from day 12 to day 14 according to a published protocol (Luo
et al., 2005) and Neuromics instructions (Neuromics, Northfield,
MN, United States). In some experiments, saclofen (30 µg,
Sigma S166) or CGP55845 (10 µg, Tocris 5584) were co-applied
in vivo with baclofen.
Statistical Analysis
Statistical analyses were conducted using SigmaPlot 12.0
software (SigmaStat, Systat Software Inc, San Jose, CA,
United States). Results were presented as mean ± standard error
of the mean (SEM). The Student’s t-test was used for two-
sample comparisons. For multiple sample comparisons, one-way
ANOVA or two-Way ANOVA followed by a Tukey post hoc test
was performed for FRET studies. One-way ANOVA followed by
a Tukey test was performed for behavioral studies. Regarding
the electrophysiology study, for all comparisons of cumulative
distributions, 2-sample Kolmogorov–Smirnov test was used.
When not indicated otherwise, the Tukey test was used. p < 0.05
was considered significant.
RESULTS
Fibulin-2 Regulates GABAB Activation
in vitro
Our first aim was to assess the consequence of GABAB/fibulin-2
interaction on the receptor conformation. We used FRET/FLIM
to measure possible changes in the distance or orientation
between GFP-GABAB1a and DsRed-GABAB2. Two-way
ANOVA revealed that incubation of primary spinal neuronal
cultures with fibulin-2, or blocking endogenous fibulin-2 with
siRNA, modified baclofen-induced fluorescence resonance
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FIGURE 1 | Fibulin-2 regulates baclofen-induced GABAB conformational changes in vitro. Fibulin-2 dose-dependently prevents agonist-induced conformational
changes. FRET efficiency is measured between GFP-GABAB1a and DsRed-GABAB2 with different concentrations of baclofen (1 nM to 1 mM) (black circles,
control). When fibulin-2 expression is inhibited with anti-fibulin-2 siRNA (blue triangles), efficacy of baclofen is increased (maximal effect of blue plot vs. black plot,
∗p < 0.05). In contrast, in cells treated with exogenous fibulin-2 protein at 25 nM (green plot), maximal effect of baclofen is decreased as compared to control
(maximal effect of fibulin-2 at 25 nM vs. control, ∗∗p < 0.01). With 50 nM of fibulin-2 (red plot), the FRET efficiency between the two subunits is abolished.
20 < n < 30. Two Way ANOVA, Tukey post hoc test: ∗p < 0.05; ∗∗p < 0.01.
energy transfer (FRET) between GABAB1a and GABAB2
receptor subunits [Figure 1; F(3,252) = 45.3, p < 0.01]. Exogenous
fibulin-2 inhibited FRET interaction in a dose-dependent
manner. At 25 nM, fibulin-2 decreases the maximal effect
(efficacy) of baclofen to induce FRET interactions between B1a
and B2 (32.2% ± 5.46 in control vs. 20% ± 5.9 in fibulin-2-treated
cultures; p < 0.01 vs. control at 10−3M baclofen). At higher
doses (50 nM), fibulin-2 totally suppressed FRET interactions.
In contrast, siRNA-mediated inhibition of fibulin-2 expression
resulted in an increase of baclofen maximal effect as measured
with FRET (32.2% ± 5.46 in control vs. 36.9% ± 6.3 in siRNA
treated cultures, p < 0.05 at 10−3M baclofen). Interestingly,
siRNA treatment also increased the efficacy of low doses of
baclofen (13.5% ± 3.02 in control vs. 23.4% ± 5 in siRNA treated
cultures; p < 0.05 vs. control at 10−9M baclofen).
Next, we tested for the effectiveness of cell-secreted fibulin-
2 to alter GABAB conformation. Fibulin-2-expressing pcDNA
plasmid was co-transfected with B1a and B2 subunits, and
FRET interactions were measured in spinal cultures as above
(Figure 2A). One-way ANOVA indicated that modifying
the amount of fibulin-2 in the primary culture has an
effect on FRET interactions [Figure 2A, F(3,36) = 93.8,
p < 0.001]. Fibulin-2 overexpression decreased baclofen-
stimulated FRET interactions (Figure 2A, 28.6% ± 5.11 in
B1a/B2 vs. 5.9% ± 0.4 in B1a/B2+fibulin-2 transfected cultures;
p < 0.001). Moreover, after fibulin-2 overexpression, baclofen-
induced FRET interactions remained in the same range as
constitutive FRET interactions, without baclofen, indicating a
nearly total suppression of baclofen effects. Fibulin-2-induced
inhibition of FRET interactions was countered by anti-fibulin-2
siRNA application, in a dose-dependent manner (Figure 2A, 20
or 40 pmol anti-fibulin-2 siRNA).
Since various cell types normally secrete fibulin-2 in the
extracellular matrix, we investigated the possible role of
endogenous fibulin-2 in restraining GABAB conformational
changes. For this purpose, we incubated spinal cultures
with anti-fibulin-2 siRNA (without overexpressing fibulin-
2) (Figure 2B). When fibulin-2 endogenous expression was
blocked with siRNA, FRET interactions were increased in
both unstimulated and baclofen-activated GABAB receptor. In
contrast, mismatch RNA had no effects on energy transfer
between GABAB subunits.
Then, we tested whether fibulin-2 was also able to inhibit the
effects of GABA, the endogenous GABAB ligand (Figure 2C). As
for baclofen, we found that fibulin-2 overexpression decreased
GABA-stimulated FRET interactions (Figure 2C, 28.5% ± 4.4
in B1a/B2 vs. 16.3% ± 2.7 in cultures overexpressing fibulin-
2; p < 0.01). Moreover, anti-fibulin-2 siRNA potentiates
the effects of GABA (Figure 2C, 28.5% ± 4.4 in B1a/B2
vs. 42% ± 4.9 in B1a/B2+siRNA vs. B1a/B2; p < 0.05)
presumably by suppressing inhibition of receptor activation by
endogenous fibulin-2.
We also checked the specificity of fibulin-2 action on the
B1/B2 heterodimer subtype. Fibulin-2 had no effect on baclofen-
stimulated FRET interactions between B2 subunit and B1b, the
other transcript variant of B1 subunit (Figure 2D; 51.2% ± 4.3
in B1b/B2 vs. 53% ± 3.9 in B1b/B2 + fibulin-2 transfected
cultures, p > 0.05, t-test). This was expected since B1b does
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FIGURE 2 | Continued
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FIGURE 2 | Fibulin-2 regulates agonist-induced GABAB activation in vitro. (A) FRET efficiency between GFP-GABAB1a and DsRed-GABAB2 ± baclofen at 10−6M.
FRET efficiency is decreased after overexpression of fibulin-2 and is restored by anti-fibulin-2 siRNA application in a dose-dependent manner (20 or 40 pmol siRNA).
∗∗∗p < 0.001 vs. “B1a/B2 + baclofen” unless indicated; ∗∗p < 0.01; (n = 21 cells). (B) FRET efficiency between GFP-GABAB1a and DsRed-GABAB2 ± baclofen at
10−6M. FRET efficiency is increased after anti-fibulin-2 siRNA application in basal conditions without baclofen (∗∗∗p < 0.001 “B1a/B2” vs. “B1a/B2 + siRNA”).
Agonist-induced receptor activation is increased after transfection with anti-fibulin-2 siRNA but not after transfection with mmRNA (n = 21 cells). ∗p < 0.05;
∗∗∗p < 0.001; n.s.: p > 0.05 vs. “B1a/B2 + baclofen” unless indicated. (C) FRET efficiency between GFP-GABAB1a and DsRed-GABAB2 ± GABA at 10−4M. FRET
efficiency is decreased after overexpression of fibulin-2. GABA effect is increased after anti-fibulin-2 siRNA application but not after mmRNA transfection
(25 < n < 35). ∗p < 0.05; ∗∗p < 0.01; n.s.: p > 0.05 vs. “B1a/B2 + GABA” unless indicated. (D) FRET efficiency between GFP-GABAB1b and
DsRed-GABAB2 ± baclofen at 10−6M. Fibulin-2 overexpression has no effect on the agonist-induced conformational changes of GABAB1b/GABAB2
(16 < n < 31). ∗p < 0.05; ∗∗∗p < 0.001; n.s.: p > 0.05 vs. “B1b/B2 + baclofen” unless indicated. (E) Fibulin-2 regulates GABAB signaling in vitro. (A) Stimulation (%
of the basal activity) of [35S]GTPγS binding observed from 1 nM of baclofen to 100 µM. Primary cell cultures of rat cortex treated with anti- fibulin-2 siRNA show
higher maximal effect than control cultures (257% ± 29 vs. 155% ± 23) but similar EC50. However, fibulin-2 treated cultures show higher EC50 than control cultures
(20 vs. 0.32 µM). Data are expressed as percentage of stimulation.
not contain the extracellular Sushi domains that bind fibulin-2
(Blein et al., 2004).
Finally, GTP binding assays were performed on membrane
extracts from cortical cell cultures (Figure 2E). In normal
conditions, baclofen facilitated G-protein coupling dose-
dependently, with a maximum effect of 155 ± 23% of
stimulation over basal values and micromolar potency
(logEC50 = −6.5 ± 0.45 µM). Fibulin-2 application decreased
the potency of baclofen on G-protein activation by two orders
of magnitude (logEC50 = −4.7 ± 0.46 µM). The increase in the
siRNA group reached up to a 100% of further stimulation by
baclofen when the maximal effect was compared with the control
group. In this siRNA group, G-protein coupling efficacy reached
a maximum effect of 257 ± 29% and a similar potency than
control group (logEC50 = −6.1 ± 0.29 µ M).
Taken together, these data show that fibulin-2 hampers
conformational changes of the GABAB receptor, both
constitutively and upon agonist application. These changes
in the GABAB conformation correlate with fibulin-2-induced
loss in G-protein coupling. Finally, we showed with a siRNA-
based strategy that endogenous fibulin-2 exerts a tonic inhibitory
effect on GABAB activation as revealed by FRET analysis and
GTP binding assay.
Mechanism of Fibulin-2 Action
With regards to the mechanisms accounting for fibulin-2-
induced impairment of GABAB activation, we first confirmed
the interaction of the ECM protein with the GABAB receptor.
Our attempts to perform co-immunoprecipitation of endogenous
fibulin-2 and GABAB receptor subunits failed and the detection
of endogenous fibulin-2 in western blot remained below the
level of sensitivity, probably due to technical issues with
immunoblotting of fibulin-2. We then switched to a cell culture
approach and performed immunoprecipitation after transfection
of tagged-proteins in COS-7 cells. Our study demonstrated
that co-immunoprecipitation of myc-GABAB1a with an anti-
myc antibody retained fibulin-2-Flag (Figure 3A, left panel) in
cultures that were triple transfected with myc-GABAB1a, HA-
GABAB2, and fibulin-2-Flag. The reverse experiments indicated
that fibulin-2-Flag also precipitated myc-GABAB1a in the same
culture model (Figure 3A, right panel). Interestingly, the co-
immunoprecipitation of myc-GABAB1a and fibulin-2-Flag was
partly lost in double transfected cell cultures, lacking the
GABAB2-expressing plasmid (Figure 3A). This suggested that
most of myc-GABAB1a was unable to bind fibulin-2-Flag, most
probably because it was not exposed to the plasma membrane in
this condition, remaining trapped in the endoplasmic reticulum
due to the relatively low amount of endogenous GABAB2
that normally ensures proper trafficking of the receptor (White
et al., 1998; Kuner et al., 1999; Margeta-Mitrovic et al.,
2000). A control experiment was conducted in cell cultures
triple transfected with myc-GABAB1b, GABAB2 and fibulin-2-
Flag (Figure 3A). No co-immunoprecipitation between myc-
GABAB1b and fibulin-2-Flag was detected in agreement with
the lack of fibulin-2-induced changes in GABAB1b/GABAB2
FRET interactions (see Figure 2D). This confirmed that fibulin-
2 interacts with GABAB1a but not GABAB1b which lacks the
fibulin-2-interacting sushi-domain.
We then considered that fibulin-2 may trigger a possible loss
of the heterodimeric state of the GABAB receptor as previously
demonstrated for the B1b/B2 post-synaptic subtype (Laffray et al.,
2007). Indeed, heterodimer dissociation would lead to similar
changes in FRET interactions and GTP binding activity. We
tested this hypothesis with co-immunoprecipitation of myc-
GABAB1a and HA-GABAB2 subunits transfected in COS-7 cells
in the presence or in the absence of fibulin-2 (Figure 3B). No
differences could be shown in B1a/B2 association in the different
conditions tested, whereby ruling out the possibility that fibulin-2
alters the dimeric state of the GABAB receptor.
Hence, we hypothesized that fibulin-2 could modify GABAB
pharmacology rather than disrupting the dimeric state. We
first tested the hypothesis that fibulin-2 modifies the affinity
of the agonist for the GABAB receptor. For this purpose,
we performed binding experiments to displace [3H]-CGP54626
by increasing concentration of baclofen after application of
exogenous fibulin-2 or anti-fibulin-2 siRNA (Figure 3C). No
effect was seen regarding the IC50 by baclofen. These data
suggest that fibulin-2 induces effects on GABAB receptors in a
more mechanical way, i.e., hampering conformational changes
of the receptor. Then, we explored changes in pharmacological
properties by studying with FRET the efficiency of GABAB
antagonists to revert baclofen activation in control conditions,
or in the absence of fibulin-2 (Figures 3D,E). As expected,
both saclofen (100 µM, Figure 3D) and CGP55845 (0.5 µM,
Figure 3E) efficiently countered baclofen-stimulated GABAB
activation. Interestingly, this antagonistic effect was abolished
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 July 2020 | Volume 14 | Article 214
fncel-14-00214 July 13, 2020 Time: 15:30 # 9
Papon et al. GABAB Inhibition by Fibulin-2
FIGURE 3 | Fibulin-2 interacts with GABAB and alters antagonist-induced effects in vitro. (A) Fibulin-2-Flag co-immunoprecipitates with myc-GABAB1a (lane 1, left
panel) in COS-7 cells. In the absence of HA-GABAB2, the co-immunoprecipitation is largely reduced (lane 2, left panel). Fibulin-2-Flag does not
co-immunoprecipitate with the GABAB1b subunit (lane 3, left panel). No signal is observed in the absence of myc-GABAB1a or fibulin-2-Flag (lane 3 and 4, left
panel). Conversely, myc-GABAB1a co-immunoprecipitates with fibulin-2-Flag (right panel). IP, immunoprecipitation; WB, Western-Blot. (B) GABAB1a-GFP subunit
co-immunoprecipitates with HA-GABAB2 in COS-7 cells in the presence (lane 1, left panel) or in the absence (lane 2, left panel) of fibulin-2-Flag. Fibulin-2-flag
transfection actually results in the expression of the protein (right panel). IP: immunoprecipitation; WB: Western-Blot. (C) One site fitting of the [3H]-CGP54626
binding sites (GABAB receptor) inhibited by baclofen in rat primary cell cultures (expressed in % of inhibition). The membrane preparations from cell cultures were
incubated with 2 nM [3H]-CGP54626 and increasing concentrations of baclofen. The affinity of the GABAB receptor to the specific agonist baclofen was similar with
fibulin-2 (); anti-fibulin-2 siRNA ( ) controls (). pIC50control: –5.0 ± 0.1; pIC50siRNA: –4.6 ± 0.1; pIC50fibulin: –4.7 ± 0.1. (D) Effects of saclofen on FRET efficiency
between GFP-GABAB1a and DsRed-GABAB2 ± baclofen at 10−6M. Baclofen effect is reversed by saclofen at 100 µM and 1 mM. Application of anti-fibulin-2
siRNA (20 or 40 pmol) suppresses this reversion at 100 µM dose (***p < 0.001 “B1a/B2 + saclo100 µM” vs. “B1a/B2 + saclo100 µM + siRNA40”). At high dose
(1 mM), saclofen remains efficient even in the presence of anti-fibulin-2 siRNA (NS: p > 0.05 “B1a/B2 + saclo1 mM” vs. “B1a/B2 + saclo1 mM + siRNA40”) (n = 21
cells). *p < 0.05; **p < 0.01; ***p < 0.001; n.s.: p > 0.05 vs. “B1a/B2 + baclofen” unless indicated. (E) Effects of CGP55845 on FRET efficiency between
GFP-GABAB1a and DsRed-GABAB2 ± baclofen at 10−6M. Baclofen effect is reversed by CGP55845 at 0.5 and 50 µM. Application of anti-fibulin-2 siRNA
(40 pmol) suppresses this reversion at 0.5 µM dose (*p < 0.05 “B1a/B2 + CGP 0.5 µM” vs. “B1a/B2 + CGP 0.5 µM + siRNA40”). At high dose (50 µM), CGP
remains efficient even in the presence of anti-fibulin-2 siRNA (NS: p > 0.05 “B1a/B2 + CGP50 µM” vs. “B1a/B2 + CGP50 µM + siRNA40”) (n = 21 cells). *p < 0.05;
**p < 0.01; ***p < 0.001; n.s.: p > 0.05 vs. “B1a/B2 + baclofen” unless indicated.
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when cultures were treated with anti-fibulin-2 siRNA. Higher
concentrations of saclofen (1 mM) or CGP55845 (50 µM) were
able to restore the antagonist efficiency, showing that fibulin-2
alters pharmacological properties, i.e., antagonist sensitivity in
presence of baclofen, of the B1a/B2 receptor subtype.
Functional Effects of Fibulin-2 on
Inhibitory Transmission
Then, we asked whether fibulin-2 modifies B1a/B2-mediated
inhibition. Since the B1a subunit is mainly found in presynaptic
compartments (Vigot et al., 2006) we focused on presynaptic
GABAB inhibition on spinal neuron cultures (Figure 4). To
further investigate the role of fibulin-2 in the control of synaptic
transmission, we analyzed the effects of baclofen (10 µM) and
saclofen (100 µM) on the amplitude and frequency distributions
of miniature excitatory EPSCs recorded in the presence of
TTX (1 µM). In preparations transfected with mismatch RNA
(Figure 4A1), comparison of the mEPSC amplitude distribution
(Figure 4A2) revealed no significant change between control and
baclofen conditions (Kolmogorov–Smirnov test, KS). Moreover,
the kinetics of averaged mEPSCs was not affected by baclofen
application (see inset in Figure 4A2). Overall, in 9 recorded
neurons, the average mEPSC amplitude remained unaltered by
baclofen application (Figure 4A3, paired t-test). By contrast, the
inter-event interval was significantly shifted toward the right
(Figure 4A4), indicating a decrease in mEPSC frequency (KS test,
p < 0.001, n = 9). Further saclofen addition (100 µM), in the
continuous presence of baclofen, induced a recovery of mEPSCs
frequency in 7 out of 9 recorded cells. Overall (Figure 4A5),
baclofen induced a significant decrease in mEPSCs frequency
to 58.2% ± 6.6 of control (p < 0.05, paired t-test). Whereas in
the presence of saclofen, the average mEPSC frequency returned
to control value (resp 91% ± 9). These results demonstrate a
clear presynaptic inhibition of excitatory synaptic transmission in
cultured spinal neurons. Similar results were obtained in control
preparations as well as preparations exposed to transfecting agent
alone (n = 9 and n = 7 respectively, data not shown).
In preparations transfected with fibulin-2 siRNA
(Figure 4B1), baclofen had no effect on the amplitude
distribution (Figure 4B2, KS test), and the kinetics of averaged
mEPSCs remained unchanged (inset in B2). No statistical effect
of baclofen on average mEPSCs amplitude could be observed
(Figure 4B3, paired t-test, n = 7). Baclofen induced a shift
in the frequency distribution curve (Figure 4B4, p < 0.001),
indicating a clear presynaptic inhibition of mEPSCs. However,
in contrast with preparations transfected with mismatch siRNA,
further saclofen application (100 µM) failed to antagonize
baclofen effects (Figure 4B2, KS test), on mEPSCs frequency.
Overall (Figure 4B5), baclofen application induced a decrease
in mEPSCs frequency to 44.4 ± 11.4% of control values in 7 out
of 7 cells (paired t-test, p < 0.05). In 5 out of these 7 neurons,
further application of saclofen did not alter mEPSC frequency
(54 ± 0.18% of control, paired-t-test, p < 0.05), showing
that the antagonist loses its capacity to block presynaptic
baclofen-induced activation of the GABAB receptor at the dose
used when fibulin-2 is knocked-down.
Finally, in preparations transfected with fibulin-2 siRNA,
the average mEPSC frequency was significantly lower than in
preparations transfected with mismatch RNA (Figure 4C1).
Importantly, this effect was preserved in the presence of baclofen
(Figure 4C1). This result indicates that the absence of fibulin-2
facilitates the action of baclofen and the presynaptic inhibitory
effect of GABAB signaling. In contrast, no change was observed
in the mean mEPSC amplitude (Figure 4C2).
Expression of Fibulin-2 in vivo
We next investigated whether changes in fibulin-2 expression
can alter GABAB inhibition in vivo. Since GABAB is involved
in the modulation of nociceptive transmission (Bowery, 2006)
we studied fibulin-2 expression in rats with spinal nerve ligation
(SNL) that induced neuropathic pain. Real-time RT-PCR showed
a marked increase in fibulin-2 mRNA levels in the dorsal spinal
cord of SNL rats ipsilateral to the injury, as compared to sham
animals (Figure 5A; One-way ANOVA, F(3,21) = 11.67, p < 0.01;
141.58% ± 7.2 in SNL rats; p < 0.01 vs. sham). Fibulin-2
overexpression was limited to the spinal cord since no increase
was noticed in the dorsal root ganglia (Figure 5B). However,
the spinal cell types that secretes fibulin-2 remain to establish.
Overexpression was specific of fibulin-2 since the expression of
the related fibulin-1 showed no changes (Figure 5C).
We checked fibulin-2 upregulation at the protein level with
immunohistochemistry. Immunostaining was hardly detectable
in control animal dorsal horn (Figure 5D1, left). Intensity
was much higher in SNL rats (Figure 5D1, right) where
discrete staining was observed. Changes in immunostaining
intensity were quantified and showed a 60% increase in the
ipsilateral dorsal horn of SNL rats as compared to sham animals
(Figure 5D2; 160.7% ± 23.7 of the sham intensity; p < 0.01,
t-test). No changes were detected in the contralateral dorsal horn
(Figure 5D2), or in the ventral horn (data not shown).
We further compared the distribution of fibulin-2 with B1a
subunit (Figure 6), and CGRP (Figure 7), a marker of peptidergic
nociceptive inputs with light and electron microscopy double
labeling experiments.
In sham animals, colocalization of fibulin-2 and B1a appeared
scarce, mainly due to the low expression level of fibulin-2
(Figures 6A1,A2a–c). Quantitative analysis confirmed that the
rate of B1a colocalization with fibulin-2 remained very limited
(Figure 6B1; 10.6 % ± 2.2 of B1a labeled area colocalized with
fibulin-2). In SNL rats, fibulin-2 was seen as discrete, intense
staining, intermingled with B1a labeling (Figures 6A1,A2d–
f). Positive signal was found surrounding cell bodies and in
processes. Overlap was much more abundant than in sham
animals (Figure 6B1; 45.8% ± 6.2 of B1a labeled area colocalized
with fibulin-2 in SNL rats, p< 0.01 vs. sham rats, t-test). However,
B1a singly labeled structures were also frequent, suggesting that
B1a/fibulin-2 interaction does occur only for a subpopulation
of B1a/B2 receptors. No changes in the B1a labeling intensity
were detected (Figure 6B2). The increased colocalization is thus
likely due to the sole up-regulation of fibulin-2 overexpression.
Electron microscopy further demonstrated that B1a and fibulin-
2 colocalized on neuronal plasma membrane (Figure 6C). Gold
particle association was found only at extra-synaptic sites. Again,
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FIGURE 4 | Continued
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FIGURE 4 | Fibulin-2 controls the sensitivity to baclofen and saclofen of GABAB-mediated presynaptic inhibition. (A1) Spontaneous miniature EPSCs (mEPSCs)
recorded from cultured spinal neurons transfected with mismatch siRNA before and after application of baclofen (10 µM) and baclofen + saclofen (100 µM). (A2)
Amplitude cumulative probability for the experiment shown in (A1). Inset trace shows superimposed average of 25 mEPSCs obtained in control and in presence of
baclofen. (A3) Inter-event interval cumulative probability for the experiment shown in (A1). The distribution is significantly shifted toward the right during baclofen
application. (A4,A5) average variation in mEPSC amplitude (A4) and frequency (A5), expressed as percent of control (n = 9). (B1) mEPSCs recorded from cultured
spinal neurons transfected with fibulin-2 siRNA before and after application of baclofen (10 µM), saclofen (100 µM), and CGP (50 µM). (B2) Amplitude cumulative
probability for the experiment shown in (B1). Inset trace shows superimposed average of 25 mEPSCs obtained in control and in presence of baclofen. (B3)
Inter-event interval cumulative probability for the experiment shown in (B1). The distribution is shifted toward the right during baclofen and baclofen + saclofen
application. (B4,B5) Average variation in mEPSC amplitude (B4) and frequency (B5), expressed as percent of control (n = 7). (C1,C2) Average frequencies (C1) and
amplitudes (C2) of mEPSCs recorded in preparations transfected with mismatch (n = 9) or anti fibulin-2 siRNA (n = 7), in control conditions and in the presence of
baclofen (10 µM).
both B1a and fibulin-2 labeling were also found independently, as
single labeling, both intracellularly and at the membrane.
Regarding fibulin-2/CGRP double labeling, both signals
were seen most often in close vicinity with light microscopy
(Figures 7a–f). Electron microscopy confirmed that fibulin-2 is
localized in the vicinity of the plasma membrane, around sensory
nerve endings filled with CGRP-containing secretory granules
(Figures 7g,h). These data suggested fibulin-2 interaction with
GABAB receptors is located, at least partly, on nociceptive nerve
endings in the spinal dorsal horn.
Functional Role of Fibulin-2 on
Neuropathic Pain Sensitization
Finally, to assess the functional role of fibulin-2 on GABAB
inhibition in chronic pain conditions, we tested the behavioral
effect of anti-fibulin-2 siRNA intrathecal injection in SNL
neuropathic rats (Figure 8). Using the von Frey test, we
compared the effects of topical intrathecal application of
baclofen and GABAB antagonist on paw withdrawal threshold
following intrathecal treatment with anti-fibulin-2 siRNA
or mismatch RNA.
One-way ANOVA indicated an effect on the withdrawal
threshold [Figure 8A; F(5,30) = 32.85, p < 0.01]. In the absence
of baclofen, anti-fibulin-2 siRNA produces a slight, though
significant, analgesic effect (Figure 8A; 40.4% ± 1.4 in SNL vs.
48.9% ± 1.9 in SNL + siRNA; p< 0.05). The injection of mmRNA
does not significantly affect the withdrawal threshold (Figure 8A;
40.4% ± 1.4 in SNL vs. 42.1% ± 2.3 in SNL + mmRNA; p< 0.05).
Interestingly, the baclofen treatments enhance the effects of anti-
fibulin-2 siRNA. More particularly, post hoc analysis shows that
the baclofen plus siRNA treatment is more efficient than baclofen
alone, or baclofen plus mmRNA to alleviate pain. Surgery resulted
in a ∼60% decrease in paw withdrawal threshold (Figure 8A).
The injection of vehicle (iFect) after surgery did not further
change the mechanical threshold of neuropathic rats (data not
shown). The injection of baclofen at day 12 after surgery induced
an increase in mechanical threshold indicating GABAB-mediated
antinociceptive effects (Figure 8A; 40.4% ± 1.4 in SNL vs.
66.8% ± 1.4 in SNL + baclo; p < 0.01). This response to
baclofen was significantly increased in SNL rats treated with anti-
fibulin-2 siRNA (Figure 8A; 66.8% ± 1.4 in SNL + baclo vs.
87.5% ± 3.9 in SNL siRNA + baclo, p < 0.01). In contrast, the
mean threshold for SNL animals was significantly increased upon
siRNA treatment after baclofen application. Changes in response
to baclofen were not observed in animals injected with mmRNA
(Figure 8A; 66.8% ± 1.4 in SNL + baclo vs. 72.0% ± 2.6 in SNL
mmRNA + baclo, p > 0.05) showing paw withdrawal threshold
similar to those observed in neuropathic rats before treatment.
The co-injection of baclofen and saclofen, in SNL rats,
reversed the effects of baclofen alone (Figure 8B; 128.12% ± 2.62
in baclofen iFect vs. 108.79% ± 7.3 in baclofen plus saclofen
iFect, p < 0.01). In the baclofen plus saclofen iFect group,
paw withdrawal threshold was similar to that measured in SNL
rats without injection, indicating the persistence of mechanical
allodynia. In contrast, after anti-fibulin-2 siRNA application,
saclofen was unable to significantly block baclofen effects. The
increase of paw withdrawal threshold remained statistically
unchanged (Figure 8B; 155.7% ± 9.4 in baclofen siRNA vs.
142.56% ± 6 in baclofen plus saclofen siRNA, p > 0.05).
In both “baclofen” and “baclofen plus saclofen” groups, the
paw withdrawal threshold was higher than after the control
iFect injection. The injection of mmRNA did not change the
effects of baclofen alone, or baclofen plus saclofen injection,
and the withdrawal threshold remained different between the
two groups (Figure 8B; 128.5% ± 5.75 in baclofen mmRNA
vs. 103.2% ± 6.7 in baclofen plus saclofen mmRNA; p< 0.05).
These data demonstrate that fibulin-2 limits GABAB receptor
inhibition in vivo. Knocking down fibulin-2 in vivo facilitates
conformational changes and activation of the receptor, therefore
enhancing GABAB-induced alleviation of pain.
DISCUSSION
In the present study, we demonstrated that: (1) fibulin-2
decreased the agonist-induced activation of GABAB receptor;
(2) fibulin-2 modified the receptor sensitivity to antagonists;
(3) fibulin-2 regulated the GABAB-mediated inhibition of
neurotransmitter release; (4) fibulin-2 was up-regulated in rat
models of neuropathic pain; (5) intrathecal knock-down of
fibulin-2 expression partially reversed mechanical allodynia in
neuropathic rats.
GABAB1a Interaction With Fibulin-2
GABAB interacting proteins were demonstrated to control
several aspects of the receptor functions (reviewed in Xu et al.,
2014) including receptor dimerization [14.3.3ζ (Couve et al.,
2001; Laffray et al., 2012)], intracellular targeting [MUPP1
(Balasubramanian et al., 2007), CHOP (Sauter et al., 2005)],
signaling transduction and desensitization [ATF4 (Vernon et al.,
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FIGURE 5 | Fibulin-2 is upregulated in the spinal cord of neuropathic rats. (A) qRT-PCR analysis of fibulin-2 mRNA in the ipsilateral spinal dorsal horn of sham rats,
neuropathic rats (SNL), and SNL rats injected with anti-fibulin-2 siRNA (SNL + siRNA) or with mismatch RNA (SNL + mmRNA). Data are expressed as percentage of
sham ± SEM. Fibulin-2 expression increased in ipsilateral dorsal horn of neuropathic rats. This increase was efficiently prevented by siRNA injection. The injection of
mmRNA had no effect on fibulin-2 expression. *p < 0.05, **p < 0.01 “sham” vs. “SNL”; n.s.: p > 0.05. (B) qRT-PCR analysis of mRNA of fibulin-2 in the ipsilateral
dorsal root ganglia of sham and neuropathic (SNL) rats. Data are expressed as percentage of sham ± SEM. No significant changes are seen (n.s.: p > 0.05 “sham”
vs. “SNL). (C) qRT-PCR analysis of mRNA of fibulin-1 in the ipsilateral spinal dorsal horn of sham and neuropathic (SNL) rats. Data are expressed as percentage of
sham ± SEM. No significant changes are observed (n.s.: p > 0.05 “sham” vs. “SNL). (D1) Immunohistochemistry for endogenous fibulin-2 in the ipsilateral dorsal
horn of sham (a), and neuropathic (SNL) (b) rats. The dotted line indicates the dorsal limit of the spinal cord section. Framed areas of the lamina II (II) in (a,b) are
displayed at higher magnification in (c,d), respectively. Fibulin-2 expression was very low in sham animals (arrowheads in c) whereas an intense staining could be
seen in the SNL group (arrowheads in d). (D2) The quantification of the signal intensity confirmed the significant difference in the ipsilateral dorsal horn between sham
and SNL groups. In contrast, no changes is seen in the contralateral dorsal horn (n = 3 sections from 7 animals in sham and SNL groups). **p < 0.01; n.s.: p > 0.05.
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FIGURE 6 | Continued
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FIGURE 6 | Endogenous co-expression of B1a and fibulin-2 in sham and neuropathic rats. (A1) Immunohistochemistry for endogenous B1a (green) and fibulin-2
(red) in lamina II (II) of the dorsal horn of sham (a), and neuropathic (SNL) (b) rats. The dotted line indicates the dorsal limit of the spinal cord section. (A2)
Micrographs are higher magnification of the framed areas in (A1) and correspond to sham (a–c), and SNL (d–f) rats. In sham animals, B1a subunit (green, arrows)
and fibulin-2 (red, arrowheads) are distributed throughout the dorsal horn but show very little colocalization. In contrast, colocalization was more frequent in SNL rats
(double arrowheads). However, some single labeling was also found for B1a (arrow) and fibulin-2. Bar = 15 µm (same for all). (B) Quantification of colocalization in
the ipsilateral dorsal horn, expressed as the percentage of B1a labeling colocalized with fibulin-2 (n = 8 sections from 3 animals in the sham group; n = 7 sections
from 3 animals in the SNL group). ∗∗p < 0.01. (C) Double immunogold labeling for B1a (15 nm colloidal gold diameter) and fibulin-2 (5 nm colloidal gold diameter) in
the ipsilateral dorsal horn of SNL rats. Both proteins colocalized at the plasma membrane of spinal neurons (double arrowheads in a,b). Gold particles association
was found essentially at extra-synaptic sites (b, the synapse is indicated with large arrows). Single fibulin-2 labeling was also found in the vicinity of the plasma
membrane (a, arrow). A, axonal nerve ending; bar = 100 nm.
FIGURE 7 | Endogenous co-expression of fibulin-2 and CGRP in neuropathic
rats. (a–f) Immunohistochemistry for endogenous fibulin-2 and CGRP in
lamina II of the dorsal horn of neuropathic (a–f) rats. Framed areas of the
lamina II (II) in a to c are displayed at higher magnification in (d–f), respectively.
CGRP (green) and fibulin-2 (red) staining was frequently seen overlapping or in
close apposition (double arrowheads). Bar = 15 µm (same for all). (g,h)
Double immunogold labeling for fibulin-2 (15 nm colloidal gold diameter) and
CGRP (5 nm colloidal gold diameter) in the ipsilateral dorsal horn of
neuropathic rats. CGRP was found in secretory granules (d,e, arrows).
Secretory granules-containing processes were surrounded by fibulin-2
labeling, at the plasma membrane (d,e, arrowheads), mostly at extra-synaptic
sites (large arrows in d). Bar = 100 nm in (d); 50 nm in (e).
2001), GRK4 (Perroy et al., 2003)]. Only few interactions between
partner proteins and the GABAB1a sushi domains have been
described. GABAB1a sushi domains play important roles in
receptor trafficking by stabilizing the GABAB1a/GABAB2 dimer
at the cell surface (Biermann et al., 2010; Hannan et al.,
2012). But the possibility that the sushi domains contribute to
signaling transduction and physiological effects of the GABAB
receptor has received only limited attention so far. However, it
has been demonstrated that targeting GABAB1a sushi domains
may impair GABAB receptor function (Tiao et al., 2008).
Actually, the most remarkable interaction was recently described
between the sushi domains and the shed amyloid-β precursor
protein ectodomain APP and its physiological effect was to
regulate GABAB1a-mediated regulation of synaptic transmission
(Rice et al., 2019).
The fibulin-2 is an extracellular matrix protein that has been
shown to interact with the GABAB1a sushi domains with yeast
two-hybrids and pull-down assays (Calver et al., 2002; Blein
et al., 2004). Fibulin-2 modulates spinal axon growth trajectories
during development (Schaeffer et al., 2018). It also mediates pro-
neurogenic effects of transforming growth factor-beta1 in adult
neural stem cells (Radice et al., 2015). Fibulin2 expression in the
central nervous system remains largely unexplored but recent
studies indicate it is produced by astrocytes (Radice et al., 2015;
Schaeffer et al., 2018). In the present study we identified the
colocalization between the GABAB receptor and the fibulin-2
in situ in the dorsal spinal cord, and we provide evidence for
a direct interaction in vitro after the overexpression of tagged
GABAB and fibulin-2 proteins.
Regulation of GABAB Receptor
Activation by Fibulin-2
We assessed the effects of fibulin-2 on GABAB receptor
activation using FLIM measurement of FRET interactions as
previously described (Laffray et al., 2012). FRET provides an
accurate measure of possible changes in the distance (<10 nm)
and/or orientation between the fluorophores. Hence, it allows
to study conformational changes between fluorescently tagged
GABAB1a (GABAB1a-GFP) and GABAB2 (GABAB2-DsRed)
receptor subunits (Fowler et al., 2007; Laffray et al., 2007).
Baclofen-induced increase in FRET efficiency between GABAB1a
and GABAB2 was demonstrated by others (Laviv et al., 2010).
In contrast, our own studies indicated that the FRET efficiency
between GABAB1b and GABAB2 is not, or slightly affected
by baclofen (Laffray et al., 2012) (see also Figure 2D of
the present study), probably because the absence of sushi
domains in the GABAB1b subunit that changes the distance
and/or the orientation of the GFP fused at the N-terminal of
the B1a/b subunits.
Fibulin-2 limits GABAB activation as demonstrated with
FRET analysis and GTP binding assay. High concentration or
overexpression of fibulin-2 is likely to increase the number
of GABAB receptors interacting with the extracellular matrix
protein, therefore impairing the overall modulatory effect of the
receptor. In contrast to the action of other GABAB partner
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FIGURE 8 | Intrathecal injection of anti-fibulin-2 siRNA potentiates the antinociceptive effect of baclofen in neuropathic rats. (A) Effects of anti-fibulin-2 siRNA and
baclofen injections in SNL rats. The effects are quantified with or without baclofen, and before (SNL, SNL + baclo) or after (SNL + siRNA, SNL + baclo + siRNA)
intrathecal injections of anti-fibulin-2 siRNA or mismatch RNA (SNL + mmRNA, SNL + baclo + mmRNA). Threshold to mechanical stimulation was measured with the
von Frey test. In the absence of baclofen, the injection of anti-fibulin-2 siRNA, but not mmRNA, induces an analgesic effect per se (*p < 0.05 “SNL” vs.
“SNL + siRNA”). Baclofen displayed an antinociceptive effect in SNL rats (**p < 0.01 “SNL” vs. “SNL + baclo”). Anti-fibulin-2 siRNA potentiated the antinociceptive
effect of baclofen in SNL rats (**p < 0.01 “SNL + Baclo” vs. “SNL + baclo + siRNA”). The withdrawal threshold remained unchanged after injection of mismatch RNA.
The withdrawal threshold before nerve ligation was set to 100%. *p < 0.05; **p < 0.01; n.s.: p > 0.05. (B) Effects of baclofen and saclofen co-application after
injections of iFect (control condition), anti-fibulin-2 siRNA (siRNA) or mismatch RNA (mmRNA) in neuropathic rats. Saclofen inhibited the baclofen effect before
anti-fibulin-2 siRNA injection (**p < 0.01 “baclofen” vs. “baclofen + saclofen”). This effect of saclofen is abolished after anti-fibulin-2 siRNA injections (n.s.: p > 0.05,
siRNA, “baclofen” vs. “baclofen + saclofen”) but not after mmRNA injection (*p < 0.05, mmRNA, “baclofen” vs. “baclofen + saclofen”). After anti-fibulin-2 siRNA
injection, the withdrawal threshold was significantly higher than after iFect injection (##p < 0.01 siRNA “baclofen + saclofen” vs. iFect “baclofen + saclofen”). The
withdrawal threshold in neuropathic rats before injection was set to 100%.
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proteins, such as 14-3-3 (Laffray et al., 2012), fibulin-2 is
unlikely to regulate the dimeric state of the receptor according
to the co-immunoprecipitation results. Therefore, we favored the
hypothesis that fibulin-2 regulates the receptor conformation.
In line with this hypothesis, the higher FRET efficacy upon
anti-fibulin-2 siRNA treatment indicated that less constraints
apply to the GABAB receptor subunits in the absence of
fibulin-2, thus increasing the probability of conformational
changes and receptor activation. Importantly, these data also
demonstrated that endogenous fibulin-2 exerted tonic inhibition
of GABAB activation.
Other examples of interactions with extracellular matrix
proteins have been shown to regulate receptor activation.
Tenascin R interacts with the B1b subunit and blocks post-
synaptic-mediated GABAB inhibition on pyramidal neurons of
the hippocampus via the HNK-1 carbohydrate (Saghatelyan et al.,
2003). The NMDA glutamate receptor interacts with the matrix
protein Reelin that regulates NMDA synaptic retention and
surface distribution (Groc et al., 2007). The activity of AMPA
receptors and their function in short-term synaptic plasticity also
depends on the interaction between receptors and extracellular
matrix proteins (Frischknecht et al., 2009).
It may be hypothesized that fibulin-2 acts through two
different modes of action, i.e., alteration of ligand affinity or
receptor conformation. However, fibulin-2 has different effects
on the action of agonists (GABA and baclofen) and competitive
antagonists (saclofen and CGP), although they interact with the
same binding site. Hence, fibulin-2 is unlikely to simply modify
ligand binding to the receptor. This is further confirmed by the
competition binding assay (Figure 3C) that indicates there is no
changes in the ligand affinity. The extracellular matrix protein
may rather alter the receptor conformation, thus changing the
GG-protein-mediated effects of agonists.
One can propose that the interaction between fibulin-2 and
the Sushi domains themselves influence the efficiency of ligands.
Indeed, a regulatory role of the Sushi domains has been shown for
glucagon and VIP receptors where the N-terminal extracellular
domain of receptor contains highly conserved amino acid
residues which are essential for its intrinsic binding activity
(Carruthers et al., 1994; Couvineau et al., 1995).
Another possible mechanism relies on fibulin-2 dimerization
(Sasaki et al., 1997). As a dimer, fibulin-2 could then bridge two
GABAB heterodimers with each other. The formation of such
higher order GABAB oligomers (Pin et al., 2009; Comps-Agrar
et al., 2011) could account for limitations of structural changes
and of GABAB activation.
Alternatively, the interaction between fibulin-2 and the Sushi
domains may also interfere with the receptor trafficking and
regulate GABAB inhibition as demonstrated for ATF4, another
interactor (Corona et al., 2018).
Consequences of Fibulin-2/GABAB
Interaction in Pain Sensitization
Nerve injury leading to pain sensitization has already been
shown to induce up-regulation of extracellular matrix proteins
in adult rats. More precisely, peripheral lesions increase the
expression of fibronectin in the dorsal spinal cord, ipsilateral
to the lesion (Nasu-Tada et al., 2006; Tsuda et al., 2008). Such
injury-induced overexpression of matrix proteins is involved
in pain sensitization by driving an increase of P2X4 receptor
expression on microglia (Tsuda et al., 2003, 2008; Ulmann et al.,
2008). Interestingly, a recent transcriptomics study indicates
that the extracellular matrix pathways are the most largely
regulated pathways in animal models of chronic pain, and
these data are corroborated by data on human low back
pain (Parisien et al., 2019), thus strengthening the hypothesis
that the extracellular matrix plays a major role in pain
sensitization processes.
The B1a/B2 heterodimer is mainly distributed in the
presynaptic compartment (Vigot et al., 2006; Biermann et al.,
2010). In superficial laminae of the spinal cord, the GABAB
receptor presynaptic inhibition is more effective to suppress
mechanical noxious transmission than innocuous transmission,
which may account for a part of the mechanism of the analgesic
effects of baclofen (Fukuhara et al., 2013). These results suggest
that GABAB receptors tonically inhibit glutamate release from
primary sensory fibers at a subset of synapses in deep dorsal horn,
being more specific of the early phase of synaptic excitation (Salio
et al., 2017). In agreement with this presynaptic localization, we
showed that fibulin-2 controlled presynaptic inhibition mediated
by the GABAB receptor. Therefore, we conclude that fibulin-2
exerts it action through interactions with the presynaptic receptor
subtypes, although post-synaptic effect cannot be ruled out. In
the spinal dorsal horn, we also showed that fibulin-2 is expressed
in superficial laminae, in the vicinity of CGRP-containing nerve
endings. The colocalization between these markers indicates that
fibulin-2 can exert its regulatory effect on primary nociceptive
afferents. Fibulin-2 up-regulation could thus limit the GABAB-
mediated suppression of neurotransmitter release by sensory
primary afferents in the superficial laminae of the dorsal horn.
Fibulin-2 could also impede GABAB presynaptic inhibition on
interneurons. In line with this role of the extracellular matrix
protein, the knockdown of fibulin-2 enhances the efficacy of
baclofen to alleviate mechanical allodynia in neuropathic rats.
Our morphological data showed that only a subset of B1a subunit
is associated to fibulin-2 at the cell surface. In line with previous
reports (Frischknecht et al., 2009), our study suggests that the
extracellular matrix protein could trap receptors, and control
their activation in specific membrane domains. It may also
restrain and filter the exchange of receptors between different
subcellular compartments.
Taken together, our data indicate that fibulin-2 overexpression
induces structural changes in the GABAB receptor that restrain
its activation by the endogenous ligand, GABA, thus allowing
a fine tuning of the receptor activation in sub-domains of the
plasma membrane.
The regulation by the extracellular matrix may also limit
the efficiency of therapeutic strategies aiming to stimulate
directly the GABAB receptor. Our data are in line with
the actual recommendations for clinical use of baclofen.
In fact, baclofen administration is not proposed in EFNS
guidelines of pharmacological treatment of neuropathic pain
(Attal et al., 2006) and its general effectiveness as an analgesic is
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limited (Bowery et al., 2002). Administration of positive allosteric
modulators may increase the effectiveness of baclofen treatment.
However, recent studies point to a limited efficacy of GABAB
allosteric modulators such as rac-BHFF in neuropathic mice
(Zemoura et al., 2016; Malcangio, 2018). To overcome this
limitation, co-application of inhibitors of extracellular matrix
proteins, or positive allosteric modulators (Zemoura et al., 2016),
together with baclofen, might provide a new mean to enhance
baclofen efficiency in clinics, without using high doses that
produce unwanted side effects such as sedation.
Together with the recent elucidation of other mechanisms
involving reduced GABA release (Moore et al., 2002) or loss
of GABAA inhibition (Coull et al., 2005; Knabl et al., 2008)
our data support the view that disinhibition dramatically twists
the excitability of spinal neurons and leads to pain sensitization
(Woolf and Salter, 2000). Targeting GABAB associated proteins,
and especially extracellular matrix proteins, may be of therapeutic
interest by enhancing the action of classical pain killers.
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